#SARSCoV2 mRNA vaccine development enabled by prototype pathogen preparedness
![]() 3656 Saturday, 13 June, 2020, 18:35 A SARS-CoV-2 vaccine is needed to control the global COVID-19 public health crisis. Atomic-level structures directed the application of prefusion-stabilizing mutations that improved expression and immunogenicity of betacoronavirus spike proteins. Using this established immunogen design, the release of SARS-CoV-2 sequences triggered immediate rapid manufacturing of an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). Here, we show that mRNA-1273 induces both potent neutralizing antibody and CD8 T cell responses and protects against SARS-CoV-2 infection in lungs and noses of mice without evidence of immunopathology. mRNA-1273 is currently in a Phase 2 clinical trial with a trajectory towards Phase 3 efficacy evaluation. |
Apple introduces the powerful new iPad Pro with the M5 chip
73515.10.2025, 23:34Apple debuts iPhone 17
298609.09.2025, 23:08Yuri Ivashechkin, the creator of the Su-25 attack aircraft, has died
356603.09.2025, 13:33Türkiye to build spaceport in Somalia for rocket, missile tests
477705.08.2025, 18:17A woman in India has been diagnosed with a unique blood type
547830.07.2025, 14:21Global media forum with Aliyev's participation to be held in occupied Stepanakert
628419.07.2025, 17:30SpaceX Starship rocket explodes during test flight (video)
852319.06.2025, 12:34Elon Musk announces XChat feature
935902.06.2025, 13:04